European journal of ophthalmology | 2021
Central retinal thickness fluctuations in patients treated with anti-VEGF for neovascular age related macular degeneration.
Abstract
PURPOSE\nThis is a retrospective, single-center, non randomized interventional real life study, investigating the correlation between variability of central retinal thickness (CRT) and functional outcomes during 2\u2009years of anti-VEGF therapy in patients treated for neovascular age related macular degeneration (nAMD).\n\n\nBACKGROUND\nCRT fluctuations can depend on various factors such as the correct timing of injections, the therapeutic algorithm, and the number of injections (NI) performed; it is important to understand if CRT fluctuations are responsible for worse visual outcomes and consequently to identify the correct ways to avoid or reduce them.\n\n\nMETHODS\nForty-one patients were treated for nAMD with aflibercept: 0.5\u2009mg intravitreal aflibercept was administered every 4\u2009weeks during the first 3\u2009months, then bimonthly over the first year, and after the first year adopting a PRN regimen. Standard deviation of CRT (CRT/SD), BCVA, and NI were recorded. Correlation studies were performed by Pearson s test, Ancova, and Principal Component Analysis.\n\n\nRESULTS\nA negative correlation was found between CRT/SD and final BCVA. In patients who lost more than 15 letters, CRT/SD mean was significantly higher in comparison with patients who lost less than 15 letters. Patients with final BCVA >65 letters showed lower CRT/SD values compared to patients with final BCVA ⩽65 letters. Multivariate analysis confirmed that in patients with higher baseline BCVA, improvement of BCVA was correlated to NI, and lower values of CRT fluctuations were observed.\n\n\nCONCLUSIONS\nCRT fluctuations, even after an appropriate NI given per year, significantly influence BCVA; a proactive treatment algorithm appears crucial when treating patients with nAMD.